NeuroSense Therapeutics Stock (NASDAQ:NRSN)

Ownership Financials Chart

Previous Close

$1.36

52W Range

$0.40 - $2.33

50D Avg

$0.86

200D Avg

$1.15

Market Cap

$26.29M

Avg Vol (3M)

$407.41K

Beta

1.50

Div Yield

-

NRSN Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IL

Employees

18

IPO Date

Dec 09, 2021

Website

NRSN Performance

NRSN Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-13.30M	$-13.55M	$-5.59M
Net Income	$-11.28M	$-11.20M	$-2.50M
EBITDA	$-13.21M	$-13.38M	$-8.28M
Basic EPS	$-0.83	$-0.97	$-1.29
Diluted EPS	$-0.83	$-0.97	$-1.29

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
BDRX	Biodexa Pharmaceuticals Plc
NTRB	Nutriband Inc.
BWV	Onconetix, Inc.
KPRX	Kiora Pharmaceuticals, Inc.
PXMD	PaxMedica, Inc. Common Stock
LGVN	Longeveron Inc.
REVB	Revelation Biosciences, Inc.
QNRX	Quoin Pharmaceuticals, Ltd.
HILS	Tharimmune, Inc.
VRAX	Virax Biolabs Group Limited
ALLR	Allarity Therapeutics, Inc.
RNXT	RenovoRx, Inc.
NRBO	NeuroBo Pharmaceuticals, Inc.